fig3

Figure 3. Glutamine metabolic reprogramming regulates sensitivity to antitumor therapy. SLC1A5: Solute carrier family 1 member 5; ASCT2: alanine, serine, cysteine-preferring transporter 2; SLC7A11: solute carrier family 7 member 11; GLS: glutaminase; cMyc: cellular Myc; GS: glutamine synthetase; MAPK: mitogen-activated protein kinase; P53: tumor protein p53; HIF2α: hypoxia-inducible factor 2 alpha; YAP1: yes-associated protein 1; Wnt: wingless-related integration site; ASNS: asparagine synthetase; mTORC1: mechanistic target of rapamycin complex 1; SREBP1: sterol regulatory element-binding protein-1; SCD5: stearoyl-coenzyme A desaturase 5.